Scientific Presentations

Scientific Presentations

All Publications

Date Focus Title of Publication
Ocotber 2023 Clinical

Determination of Optimal Eosinophil Thresholds for Diagnosis of Eosinophilic Gastritis and Duodenitis: A Pooled Analysis of 4 Prospective Studies

Clinical and Translational Gastroenterology

August 2023 Clinical

Mast Cell Silencing: A Novel Therapeutic Approach for Urticaria and Other Mast Cell-Mediated Diseases

Allergy

June 2023 Preclinical

Siglec-6 and Siglec-8 Show Distinct Differences in Regulating Mast Cell Function

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

April 2023 Clinical

Phase 2 Trial in Progress: Lirentelimab in Adults with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments

Revolutionizing Atopic Dermatitis (RAD)

February 2023 Preclinical

An Agonistic Monoclonal Antibody Against Siglec-6 Broadly Inhibits Mast Cell Activation in Transgenic Mice

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

December 2022 Clinical

High Discovery Rate of Duodenal and Gastric Eosinophilia in Patients with Unexplained Moderate-Severe Abdominal Symptoms: A Prospective US Multi-Site Study

Gastroenterology 

December 2022 Clinical

Phase 2 Trial in Progress: Lirentelimab in Adults with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments

Revolutionizing Atopic Dermatitis (RAD)

December 2022 Clinical

Targeting the Inhibitory Receptor Siglec-8 on Mast Cells Represents an Attractive Approach to Reduce MRGPRX2-Mediated Mast Cell Activation

Revolutionizing Atopic Dermatitis (RAD)

December 2022 Clinical

Lirentelimab for Antihistamine-Refractory Chronic Spontaneous Urticaria — Phase 2 Trial in Progress

Global Urticaria Forum (GUF)

December 2022 Clinical

Lirentelimab for Antihistamine-Resistant Chronic Spontaneous and Inducible Urticaria — Proof-of-Concept Results

Global Urticaria Forum (GUF)

November 2022 Disease State

Gastroenterology Practice Patterns Contribute to Missed Diagnoses of Eosinophilic Gastritis and Duodenitis

Gastro Hep Advances

November 2022 Preclinical

Discovery of an Agonistic Siglec-6 Antibody That Inhibits and Reduces Human Mast Cells

Communications Biology

November 2022 Preclinical

Antibody Blockade of the Immunoinhibitory Receptor Siglec-10 Polarizes Tumor-associated Myeloid Cells and Promotes Anti-tumor Immunity

Society for Immunotherapy of Cancer (SITC)

October 2022 Clinical

Results from KRYPTOS, a Phase 2/3 Study of Lirentelimab (AK002) in Adults and Adolescents with EoE

American College of Gastroenterology (ACG)

October 2022 Clinical

Lirentelimab (AK002) Safety and Efficacy in Patients with Higher Eosinophil Thresholds: Supplementary Analysis of Phase 2/3 EoE KRYPTOS Trial

American College of Gastroenterology (ACG)

July 2022 Preclinical

Siglec-6 Interacts with KIT/CD117, Recruits Shp Phosphatases and Inhibits SCF-Mediated Inflammation

Mast Cell and Basophil Research Network (EMBRN) Annual Meeting

July 2022 Clinical

Lirentelimab Reduces Levels of Inflammatory Cytokines in Tear Fluid From Patients With Allergic Conjunctivitis

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

July 2022 Preclinical

The Inhibitory Receptor Siglec-8 Interacts with FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

July 2022 Preclinical

MRGPRX2 Mediates Mast Cell Activation and Neurogenic Inflammation in Lesional Biopsies From Patients With Atopic Dermatitis

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

July 2022 Preclinical

An Agonistic Monoclonal Antibody Against Siglec-6 Selectively Inhibits and Reduces Human Tissue Mast Cells

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2022 Disease State

The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States

Advances in Therapy

May 2022 Clinical

Determination of Optimal Eosinophil Thresholds for Diagnosis of Eosinophilic Gastritis and Duodenitis: A Pooled Analysis of 4 Prospective Adult Studies

Digestive Disease Week (DDW)

April 2022 Clinical

Lirentelimab for Severe and Chronic Forms of Allergic Conjunctivitis

Journal of Allergy and Clinical Immunology (JACI)

February 2022 Preclinical

Mast Cells are Locally Activated and Respond to MRGPRX2 Stimulation in Atopic Dermatitis Ex Vivo Skin Biopsies

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

January 2022 Preclinical

The Inhibitory Receptor Siglec-8 Interacts with FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation

Frontiers in Immunology

January 2022 Clinical

An Open-Label, Proof-of-Concept Study of Lirentelimab for Antihistamine-Resistant Chronic Spontaneous and Inducible Urticaria

Journal of Allergy and Clinical Immunology (JACI)

November 2021 Preclinical

Mast Cell Activation is Associated With Post-Acute COVID-19 Syndrome

Allergy

October 2021 Disease State

Peripheral Eosinophils, Total IgE, and Atopy in Newly Identified Patients with Gastroduodenal Eosinophilia

American College of Allergy, Asthma, & Immunology (ACAAI)

October 2021 Disease State

High Discovery Rate of Eosinophilic Gastritis and/or Duodenitis Among Patients with Chronic Unexplained Gastrointestinal Symptoms

American College of Gastroenterology (ACG)

October 2021 Clinical

Patients With Eosinophilic Esophagitis and Gastrointestinal Symptoms May Have Eosinophilic Gastritis and/or Duodenitis, Not Associated With Peak Esophageal Eosinophil Count

American College of Gastroenterology (ACG)

October 2021 Clinical

Safety and Efficacy of Long-Term Treatment With Lirentelimab, a Monoclonal Antibody Against Siglec-8, in Patients With Eosinophilic Gastritis and/or Duodenitis

American College of Gastroenterology (ACG)

October 2021 Clinical

Similar Efficacy of Lirentelimab in Patients With New vs Established Diagnoses of Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial

American College of Gastroenterology (ACG)

October 2021 Clinical

Systematic Collection of Biopsies and Quantification of Eosinophils in Multiple High-Power Fields is Required for Diagnosis of Eosinophilic Gastritis and/or Duodenitis

American College of Gastroenterology (ACG)

October 2021 Clinical

General Pathologists Did Not Routinely Evaluate Gastric or Duodenal Eosinophilia

American College of Gastroenterology (ACG)

October 2021 Clinical

Lirentelimab, A Monoclonal Antibody Against Siglec-8, Depletes Blood and Tissue Eosinophils in Patients With Allergic or Inflammatory Diseases

International Eosinophil Society (IES)

October 2021 Disease State

High Discovery Rate of Eosinophilic Gastritis and/or Duodenitis Among Patients with Chronic Functional Gastrointestinal Symptoms

United European Gastroenterology Week (UEGW)

October 2021 Clinical

Safety and Efficacy of Long-Term Treatment With Lirentelimab, a Monoclonal Antibody Against Siglec-8, in Patients With Eosinophilic Gastritis/Duodenitis

United European Gastroenterology Week (UEGW)

September 2021 Disease State

High Discovery Rate of Gastroduodenal Eosinophilia but not Eosinophilic Esophagitis in Patients with Chronic Gastrointestinal Symptoms

International Society for Diseases of the Esophagus (ISDE)

September 2021 Clinical

Long-term Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Lirentelimab, a Monoclonal Antibody Against Siglec-8

International Society for Diseases of the Esophagus (ISDE)

September 2021 Clinical

Gastroduodenal Eosinophilia Is Under-Appreciated In Eosinophilic Esophagitis (EoE) Patients With Functional Bowel Symptoms: A Real Life Experience

International Society for Diseases of the Esophagus (ISDE)

September 2021 Clinical

Histopathologic Diagnostic Criteria for Eosinophilic Gastritis and Eosinophilic Duodenitis

College of American Pathologists (CAP)

September 2021 Clinical

A Systematic Histopathology Protocol Led to Discovery of the High Prevalence of Eosinophilic Gastritis and/or Eosinophilic Duodenitis in Patients with Moderate–Severe Gastrointestinal Symptoms: Results from 2 Prospective Studies

College of American Pathologists (CAP)

July 2021 Clinical

High Discovery Rate of Previously Undiagnosed Patients with Eosinophilic Gastritis and Duodenitis Using a Systematic Endoscopic Biopsy Protocol: Screening Data Analysis from ENIGMA, a Randomized Controlled Trial

American Partnership for Eosinophilic Disorders (APFED)

July 2021 Clinical

Gastroduodenal Eosinophilia Is Under-Appreciated In Eosinophilic Esophagitis (EoE) Patients With Functional Bowel Symptoms: A Real Life Experience

American Partnership for Eosinophilic Disorders (APFED)

July 2021 Preclinical

Mast Cells are Locally Activated and Express Functional MRGPRX2 in Biopsies from Symptomatic Eosinophilic Gastritis and Duodenitis Patients

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

July 2021 Disease State

Peripheral Eosinophils and Total IgE Are Not Elevated in Most Newly Identified Patients With Gastroduodenal Eosinophilia

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2021 Clinical

Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab

Clinical Gastroenterology and Hepatology

May 2021 Disease State

Endoscopy and Systematic Biopsy of Patients with Chronic Gastrointestinal Symptoms Leads to High Discovery Rate of Patients Who Meet Histologic Criteria for Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Long-term Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Lirentelimab, a Monoclonal Antibody Against Siglec-8

Digestive Disease Week (DDW) Annual Meeting

May 2021 Disease State

Activated Mast Cells and Eosinophils are Associated with Increased Inflammatory Mediators in Mucosal Biopsies from EG and/or EoD Patients with Chronic Gastrointestinal Symptoms

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Gastroduodenal Eosinophilia Is Under-Appreciated In Eosinophilic Esophagitis (EoE) Patients With Functional Bowel Symptoms: A Real Life Experience

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Optimization of Eosinophilic Gastritis/Duodenitis Detection Requires Evaluation of Multiple High-Powered Fields in Each of 8 Gastric and 4 Duodenal Biopsies: Analysis from a Randomized Trial

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Eosinophilic Gastritis and Eosinophilic Duodenitis Exhibit a Similar Clinical Presentation, Underscoring the Need for Collection of Multiple Biopsies From Both the Stomach and Duodenum to Evaluate for Tissue Eosinophilia

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Endoscopic Appearance Does Not Predict the Presence of Histologic Eosinophilic Gastritis Among Symptomatic Adults, Indicating That Collection and Evaluation of Biopsies Should Occur Regardless of Endoscopic Appearance: Analysis From a Randomized Trial

Digestive Disease Week (DDW) Annual Meeting

March 2021 Preclinical

Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody 

Front. Immunol.

January 2021 Clinical

Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study

The Journal of Allergy and Clinical Immunology: In Practice

November 2020 Preclinical

Discovery, Function, and Therapeutic Targeting of Siglec-8

Cells

October 2020 Clinical

Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis

New England Journal of Medicine

June 2020 Preclinical

An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells

Clinical & Experimental Allergy

August 2020 Preclinical

A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation

Mucosal Immunology

June 2020 Preclinical

An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells

Clinical & Experimental Allergy

June 2020 Clinical

Treatment of Severe Allergic Conjunctivitis with AK002 Indicated Improvement of Ocular Signs and Symptoms and Reduction of Severity of Comorbid Atopic Diseases in a Phase 1b Open-Label Study

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2020 Preclinical

A Siglec-8 Antibody Reduces Substance P-induced Inflammation by Inhibiting MRGPR-mediated Mast Cell Activation

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

May 2020 Clinical

Interim Results of an Open-label Extension Study of Lirentelimab, an Anti-Siglec-8 Antibody, for the Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Digestive Disease Week (DDW) Annual Meeting

May 2020 Clinical

Primary Results of A Phase 1 Multicenter Open- Label Study of Lirentelimab, An Anti-Siglec-8 Antibody, for the Treatment of Patients With Chronic Gastrointestinal Symptoms and Elevated Gastric and/or Duodenal Mast Cells

Digestive Disease Week (DDW) Annual Meeting

May 2020 Disease State

Mast Cells Are Significantly Activated In Patients with Ulcerative Colitis and Are Inhibited by an Anti-Siglec-8 Antibody, Lirentelimab (AK002)

Digestive Disease Week (DDW) Annual Meeting

May 2020 Disease State

EGID Biopsies Have Functionally Distinct and Activated Mast Cells That Contribute to Disease Pathogenesis and Are Inhibited By an Anti-Siglec-8 Antibody, Lirentelimab (AK002)

Digestive Disease Week (DDW) Annual Meeting

May 2020 Clinical

Histologic and Symptomatic Improvement Across Multiple Forms of Eosinophilic Gastrointestinal Diseases in ENIGMA, a Randomized, Double-Blind, Placebo-Controlled Trial of Lirentelimab (AK002)

Digestive Disease Week (DDW) Annual Meeting

March 2020 Clinical

AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Clinical

Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic Urticaria (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Preclinical

AK002, an Anti-Siglec-8 Antibody, Suppresses Acute IL-33-induced Neutrophil Infiltration and Attenuates Tissue Damage in a Chronic Experimental COPD Model Through Mast Cell Inhibition (#568) (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Clinical

Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study) (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Preclinical

Atopic Dermatitis Skin Biopsies Have High Numbers of Activated Mast Cells that are Inhibited by AK002 after Stimulation Ex Vivo (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Disease State

EoE Biopsies have Elevated and Activated Mast Cells that Produce Cytokines and Chemokines that Drive Disease Pathogenesis (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Disease State

A Longitudinal, Population-Based Study of the Difficult Journey to Diagnosis Endured by Patients with Eosinophilic Gastritis and Eosinophilic Gastroenteritis (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

January 2020 Preclinical

Lirentelimab (AK002), an Anti-Siglec-8 Antibody, Inhibits IL-33-mediated Mast Cell Activation and Neutrophilic Inflammation (pdf)

Gordon Research Conference on Food Allergy in the Context of Mucosal Homeostasis and Immunity

January 2020 Disease State

Phenotypic Characterization of Inflammatory Bowel Disease Biopsies Reveal That Mast Cells Are Significantly Elevated and Activated In Patients with Ulcerative Colitis (pdf)

Crohn’s & Colitis Congress

November 2019 Disease State

Time to Diagnosis of Eosinophilic Gastritis and Eosinophilic Enteritis Improves When Patients Are Co-Managed by an Allergist and Gastroenterologist (pdf)

American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting

October 2019 Clinical

Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Gastroenteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia (pdf)

American College of Gastroenterology (ACG) Annual Meeting

October 2019 Disease State

Additional Support Needed for Successful Transition of Care from Pediatric to Adult Providers for the Management of Eosinophilic Gastrointestinal Diseases (pdf)

American College of Gastroenterology (ACG) Annual Meeting

October 2019 Disease State

Eosinophilic Gastritis and Eosinophilic Enteritis Patients Endure a Lengthy Path to Diagnosis and Experience Persistent Symptoms After Diagnosis (pdf)

American College of Gastroenterology (ACG) Annual Meeting

October 2019 Clinical

Efficacy and Safety of AK002 in Adult Patients with Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis: Primary Results from a Randomized, Double-Blind Placebo-Controlled Phase 2 Trial (ENIGMA Study) (pdf)

American College of Gastroenterology (ACG) Annual Meeting

August 2019 Preclinical

AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice

International Archives of Allergy and Immunology

August 2019 Preclinical

Siglec-8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis

JCI Insight

June 2019 Preclinical

Inhibition of Mast Cells with a Siglec-8 Antibody Reduces Tissue Damage in Models of Skin and Lung Fibrosis and COPD

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2019 Preclinical

Eosinophilic Esophagitis and Gastritis Patient Biopsies Have High Levels of Activated Eosinophils and Mast Cells That Are Inhibited by AK002 (pdf)

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2019 Clinical

Efficacy and Safety Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Multiple Forms of Uncontrolled Chronic Urticaria (CU): Results from an Open-label Phase 2a Study (pdf)

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2019 Clinical

Safety and Efficacy Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Indolent Systemic Mastocytosis (ISM): Results from a First-in-Human, Open-label Phase 1 Study (pdf)

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2019 Disease State

The Tortuous Path to Diagnosis of Eosinophilic Gastritis and Eosinophilic Gastroenteritis (EG/EGE) in the United States: A Real-World, Population-Based Study (pdf)

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

May 2019 Disease State

Mast Cells in Addition to Eosinophils Are Markedly Elevated in Patients with Eosinophilic Gastritis and/or Gastroenteritis (pdf)

Digestive Disease Week (DDW) Annual Meeting

November 2018 Preclinical

AK002, a Novel Siglec-8 Antibody Depletes Human Eosinophils and Inhibits Anaphylaxis in Humanized Mice

American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting

March 2018 Clinical

Phase 1 Double-Blind, Placebo-Controlled, Ascending Dose Study of Siglec-8 Selective mAb AK002 in Healthy Subjects

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

Clinical

Date Focus Title of Publication
Ocotber 2023 Clinical

Determination of Optimal Eosinophil Thresholds for Diagnosis of Eosinophilic Gastritis and Duodenitis: A Pooled Analysis of 4 Prospective Studies

Clinical and Translational Gastroenterology

August 2023 Clinical

Mast Cell Silencing: A Novel Therapeutic Approach for Urticaria and Other Mast Cell-Mediated Diseases

Allergy

April 2023 Clinical

Phase 2 Trial in Progress: Lirentelimab in Adults with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments

Revolutionizing Atopic Dermatitis (RAD)

December 2022 Clinical

High Discovery Rate of Duodenal and Gastric Eosinophilia in Patients with Unexplained Moderate-Severe Abdominal Symptoms: A Prospective US Multi-Site Study

Gastroenterology 

December 2022 Clinical

Phase 2 Trial in Progress: Lirentelimab in Adults with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments

Revolutionizing Atopic Dermatitis (RAD)

December 2022 Clinical

Targeting the Inhibitory Receptor Siglec-8 on Mast Cells Represents an Attractive Approach to Reduce MRGPRX2-Mediated Mast Cell Activation

Revolutionizing Atopic Dermatitis (RAD)

December 2022 Clinical

Lirentelimab for Antihistamine-Refractory Chronic Spontaneous Urticaria — Phase 2 Trial in Progress

Global Urticaria Forum (GUF)

December 2022 Clinical

Lirentelimab for Antihistamine-Resistant Chronic Spontaneous and Inducible Urticaria — Proof-of-Concept Results

Global Urticaria Forum (GUF)

October 2022 Clinical

Results from KRYPTOS, a Phase 2/3 Study of Lirentelimab (AK002) in Adults and Adolescents with EoE

American College of Gastroenterology (ACG)

October 2022 Clinical

Lirentelimab (AK002) Safety and Efficacy in Patients with Higher Eosinophil Thresholds: Supplementary Analysis of Phase 2/3 EoE KRYPTOS Trial

American College of Gastroenterology (ACG)

July 2022 Clinical

Lirentelimab Reduces Levels of Inflammatory Cytokines in Tear Fluid From Patients With Allergic Conjunctivitis

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

May 2022 Clinical

Determination of Optimal Eosinophil Thresholds for Diagnosis of Eosinophilic Gastritis and Duodenitis: A Pooled Analysis of 4 Prospective Adult Studies

Digestive Disease Week (DDW)

April 2022 Clinical

Lirentelimab for Severe and Chronic Forms of Allergic Conjunctivitis

Journal of Allergy and Clinical Immunology (JACI)

January 2022 Clinical

An Open-Label, Proof-of-Concept Study of Lirentelimab for Antihistamine-Resistant Chronic Spontaneous and Inducible Urticaria

Journal of Allergy and Clinical Immunology (JACI)

October 2021 Clinical

Patients With Eosinophilic Esophagitis and Gastrointestinal Symptoms May Have Eosinophilic Gastritis and/or Duodenitis, Not Associated With Peak Esophageal Eosinophil Count

American College of Gastroenterology (ACG)

October 2021 Clinical

Safety and Efficacy of Long-Term Treatment With Lirentelimab, a Monoclonal Antibody Against Siglec-8, in Patients With Eosinophilic Gastritis and/or Duodenitis

American College of Gastroenterology (ACG)

October 2021 Clinical

Similar Efficacy of Lirentelimab in Patients With New vs Established Diagnoses of Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial

American College of Gastroenterology (ACG)

October 2021 Clinical

Systematic Collection of Biopsies and Quantification of Eosinophils in Multiple High-Power Fields is Required for Diagnosis of Eosinophilic Gastritis and/or Duodenitis

American College of Gastroenterology (ACG)

October 2021 Clinical

General Pathologists Did Not Routinely Evaluate Gastric or Duodenal Eosinophilia

American College of Gastroenterology (ACG)

October 2021 Clinical

Lirentelimab, A Monoclonal Antibody Against Siglec-8, Depletes Blood and Tissue Eosinophils in Patients With Allergic or Inflammatory Diseases

International Eosinophil Society (IES)

October 2021 Clinical

Safety and Efficacy of Long-Term Treatment With Lirentelimab, a Monoclonal Antibody Against Siglec-8, in Patients With Eosinophilic Gastritis/Duodenitis

United European Gastroenterology Week (UEGW)

September 2021 Clinical

Long-term Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Lirentelimab, a Monoclonal Antibody Against Siglec-8

International Society for Diseases of the Esophagus (ISDE)

September 2021 Clinical

Gastroduodenal Eosinophilia Is Under-Appreciated In Eosinophilic Esophagitis (EoE) Patients With Functional Bowel Symptoms: A Real Life Experience

International Society for Diseases of the Esophagus (ISDE)

September 2021 Clinical

Histopathologic Diagnostic Criteria for Eosinophilic Gastritis and Eosinophilic Duodenitis

College of American Pathologists (CAP)

September 2021 Clinical

A Systematic Histopathology Protocol Led to Discovery of the High Prevalence of Eosinophilic Gastritis and/or Eosinophilic Duodenitis in Patients with Moderate–Severe Gastrointestinal Symptoms: Results from 2 Prospective Studies

College of American Pathologists (CAP)

July 2021 Clinical

High Discovery Rate of Previously Undiagnosed Patients with Eosinophilic Gastritis and Duodenitis Using a Systematic Endoscopic Biopsy Protocol: Screening Data Analysis from ENIGMA, a Randomized Controlled Trial

American Partnership for Eosinophilic Disorders (APFED)

July 2021 Clinical

Gastroduodenal Eosinophilia Is Under-Appreciated In Eosinophilic Esophagitis (EoE) Patients With Functional Bowel Symptoms: A Real Life Experience

American Partnership for Eosinophilic Disorders (APFED)

June 2021 Clinical

Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab

Clinical Gastroenterology and Hepatology

May 2021 Clinical 

Long-term Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Lirentelimab, a Monoclonal Antibody Against Siglec-8

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Gastroduodenal Eosinophilia Is Under-Appreciated In Eosinophilic Esophagitis (EoE) Patients With Functional Bowel Symptoms: A Real Life Experience

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Optimization of Eosinophilic Gastritis/Duodenitis Detection Requires Evaluation of Multiple High-Powered Fields in Each of 8 Gastric and 4 Duodenal Biopsies: Analysis from a Randomized Trial

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Eosinophilic Gastritis and Eosinophilic Duodenitis Exhibit a Similar Clinical Presentation, Underscoring the Need for Collection of Multiple Biopsies From Both the Stomach and Duodenum to Evaluate for Tissue Eosinophilia

Digestive Disease Week (DDW) Annual Meeting

May 2021 Clinical 

Endoscopic Appearance Does Not Predict the Presence of Histologic Eosinophilic Gastritis Among Symptomatic Adults, Indicating That Collection and Evaluation of Biopsies Should Occur Regardless of Endoscopic Appearance: Analysis From a Randomized Trial

Digestive Disease Week (DDW) Annual Meeting

January 2021 Clinical

Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study

The Journal of Allergy and Clinical Immunology: In Practice

October 2020 Clinical

Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis

New England Journal of Medicine

June 2020 Preclinical

An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells

Clinical & Experimental Allergy

June 2020 Clinical

Treatment of Severe Allergic Conjunctivitis with AK002 Indicated Improvement of Ocular Signs and Symptoms and Reduction of Severity of Comorbid Atopic Diseases in a Phase 1b Open-Label Study

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

May 2020 Clinical

Interim Results of an Open-label Extension Study of Lirentelimab, an Anti-Siglec-8 Antibody, for the Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Digestive Disease Week (DDW) Annual Meeting

May 2020 Clinical

Primary Results of A Phase 1 Multicenter Open- Label Study of Lirentelimab, An Anti-Siglec-8 Antibody, for the Treatment of Patients With Chronic Gastrointestinal Symptoms and Elevated Gastric and/or Duodenal Mast Cells

Digestive Disease Week (DDW) Annual Meeting

May 2020 Clinical

Histologic and Symptomatic Improvement Across Multiple Forms of Eosinophilic Gastrointestinal Diseases in ENIGMA, a Randomized, Double-Blind, Placebo-Controlled Trial of Lirentelimab (AK002)

Digestive Disease Week (DDW) Annual Meeting

March 2020 Clinical

AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Clinical

Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic Urticaria (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Clinical

Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study) (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

October 2019 Clinical

Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Gastroenteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia (pdf)

American College of Gastroenterology (ACG) Annual Meeting

October 2019 Clinical

Efficacy and Safety of AK002 in Adult Patients with Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis: Primary Results from a Randomized, Double-Blind Placebo-Controlled Phase 2 Trial (ENIGMA Study) (pdf)

American College of Gastroenterology (ACG) Annual Meeting

June 2019 Clinical

Efficacy and Safety Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Multiple Forms of Uncontrolled Chronic Urticaria (CU): Results from an Open-label Phase 2a Study (pdf)

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2019 Clinical

Safety and Efficacy Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Indolent Systemic Mastocytosis (ISM): Results from a First-in-Human, Open-label Phase 1 Study (pdf)

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

March 2018 Clinical

Phase 1 Double-Blind, Placebo-Controlled, Ascending Dose Study of Siglec-8 Selective mAb AK002 in Healthy Subjects

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

Preclinical

Date Focus Title of Publication
June 2023 Preclinical

Siglec-6 and Siglec-8 Show Distinct Differences in Regulating Mast Cell Function

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

February 2023 Preclinical

An Agonistic Monoclonal Antibody Against Siglec-6 Broadly Inhibits Mast Cell Activation in Transgenic Mice

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

November 2022 Preclinical

Discovery of an Agonistic Siglec-6 Antibody That Inhibits and Reduces Human Mast Cells

Communications Biology

November 2022 Preclinical

Antibody Blockade of the Immunoinhibitory Receptor Siglec-10 Polarizes Tumor-associated Myeloid Cells and Promotes Anti-tumor Immunity

Society for Immunotherapy of Cancer (SITC)

July 2022 Preclinical

Siglec-6 Interacts with KIT/CD117, Recruits Shp Phosphatases and Inhibits SCF-Mediated Inflammation

Mast Cell and Basophil Research Network (EMBRN) Annual Meeting

July 2022 Preclinical

The Inhibitory Receptor Siglec-8 Interacts with FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

July 2022 Preclinical

MRGPRX2 Mediates Mast Cell Activation and Neurogenic Inflammation in Lesional Biopsies From Patients With Atopic Dermatitis

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

July 2022 Preclinical

An Agonistic Monoclonal Antibody Against Siglec-6 Selectively Inhibits and Reduces Human Tissue Mast Cells

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

February 2022 Preclinical

Mast Cells are Locally Activated and Respond to MRGPRX2 Stimulation in Atopic Dermatitis Ex Vivo Skin Biopsies

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

January 2022 Preclinical

The Inhibitory Receptor Siglec-8 Interacts with FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation

Frontiers in Immunology

November 2021 Preclinical

Mast Cell Activation is Associated With Post-Acute COVID-19 Syndrome

Allergy

July 2021 Preclinical

Mast Cells are Locally Activated and Express Functional MRGPRX2 in Biopsies from Symptomatic Eosinophilic Gastritis and Duodenitis Patients

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

March 2021 Preclinical

Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody 

Front. Immunol.

November 2020 Preclinical

Discovery, Function, and Therapeutic Targeting of Siglec-8

Cells

August 2020 Preclinical

A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation

Mucosal Immunology

June 2020 Preclinical

An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells

Clinical & Experimental Allergy

June 2020 Preclinical

A Siglec-8 Antibody Reduces Substance P-induced Inflammation by Inhibiting MRGPR-mediated Mast Cell Activation

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

March 2020 Preclinical

AK002, an Anti-Siglec-8 Antibody, Suppresses Acute IL-33-induced Neutrophil Infiltration and Attenuates Tissue Damage in a Chronic Experimental COPD Model Through Mast Cell Inhibition (#568) (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Preclinical

Atopic Dermatitis Skin Biopsies Have High Numbers of Activated Mast Cells that are Inhibited by AK002 after Stimulation Ex Vivo (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

January 2020 Preclinical

Lirentelimab (AK002), an Anti-Siglec-8 Antibody, Inhibits IL-33-mediated Mast Cell Activation and Neutrophilic Inflammation (pdf)

Gordon Research Conference on Food Allergy in the Context of Mucosal Homeostasis and Immunity

August 2019 Preclinical

AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice

International Archives of Allergy and Immunology

August 2019 Preclinical

Siglec-8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis

JCI Insight

June 2019 Preclinical

Inhibition of Mast Cells with a Siglec-8 Antibody Reduces Tissue Damage in Models of Skin and Lung Fibrosis and COPD

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

June 2019 Preclinical

Eosinophilic Esophagitis and Gastritis Patient Biopsies Have High Levels of Activated Eosinophils and Mast Cells That Are Inhibited by AK002 (pdf)

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

November 2018 Preclinical

AK002, a Novel Siglec-8 Antibody Depletes Human Eosinophils and Inhibits Anaphylaxis in Humanized Mice

American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting

Disease State

Date Focus Title of Publication
November 2022 Disease State

Gastroenterology Practice Patterns Contribute to Missed Diagnoses of Eosinophilic Gastritis and Duodenitis

Gastro Hep Advances

June 2022 Disease State

The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States

Advances in Therapy

October 2021 Disease State

Peripheral Eosinophils, Total IgE, and Atopy in Newly Identified Patients with Gastroduodenal Eosinophilia

American College of Allergy, Asthma, & Immunology (ACAAI)

October 2021 Disease State

High Discovery Rate of Eosinophilic Gastritis and/or Duodenitis Among Patients with Chronic Unexplained Gastrointestinal Symptoms

American College of Gastroenterology (ACG)

October 2021 Disease State

High Discovery Rate of Eosinophilic Gastritis and/or Duodenitis Among Patients with Chronic Unexplained Gastrointestinal Symptoms

American College of Gastroenterology (ACG)

October 2021 Disease State

High Discovery Rate of Eosinophilic Gastritis and/or Duodenitis Among Patients with Chronic Functional Gastrointestinal Symptoms

United European Gastroenterology Week (UEGW)

September 2021 Disease State

High Discovery Rate of Gastroduodenal Eosinophilia but not Eosinophilic Esophagitis in Patients with Chronic Gastrointestinal Symptoms

International Society for Diseases of the Esophagus (ISDE)

July 2021 Disease State

Peripheral Eosinophils and Total IgE Are Not Elevated in Most Newly Identified Patients With Gastroduodenal Eosinophilia

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

May 2021 Disease State

Endoscopy and Systematic Biopsy of Patients with Chronic Gastrointestinal Symptoms Leads to High Discovery Rate of Patients Who Meet Histologic Criteria for Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Digestive Disease Week (DDW) Annual Meeting

May 2021 Disease State

Activated Mast Cells and Eosinophils are Associated with Increased Inflammatory Mediators in Mucosal Biopsies from EG and/or EoD Patients with Chronic Gastrointestinal Symptoms

Digestive Disease Week (DDW) Annual Meeting

May 2020 Disease State

Mast Cells Are Significantly Activated In Patients with Ulcerative Colitis and Are Inhibited by an Anti-Siglec-8 Antibody, Lirentelimab (AK002)

Digestive Disease Week (DDW) Annual Meeting

May 2020 Disease State

EGID Biopsies Have Functionally Distinct and Activated Mast Cells That Contribute to Disease Pathogenesis and Are Inhibited By an Anti-Siglec-8 Antibody, Lirentelimab (AK002)

Digestive Disease Week (DDW) Annual Meeting

March 2020 Disease State

EoE Biopsies have Elevated and Activated Mast Cells that Produce Cytokines and Chemokines that Drive Disease Pathogenesis (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

March 2020 Disease State

A Longitudinal, Population-Based Study of the Difficult Journey to Diagnosis Endured by Patients with Eosinophilic Gastritis and Eosinophilic Gastroenteritis (pdf)

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

January 2020 Disease State

Phenotypic Characterization of Inflammatory Bowel Disease Biopsies Reveal That Mast Cells Are Significantly Elevated and Activated In Patients with Ulcerative Colitis (pdf)

Crohn’s & Colitis Congress

November 2019 Disease State

Time to Diagnosis of Eosinophilic Gastritis and Eosinophilic Enteritis Improves When Patients Are Co-Managed by an Allergist and Gastroenterologist (pdf)

American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting

October 2019 Disease State

Additional Support Needed for Successful Transition of Care from Pediatric to Adult Providers for the Management of Eosinophilic Gastrointestinal Diseases (pdf)

American College of Gastroenterology (ACG) Annual Meeting

October 2019 Disease State

Eosinophilic Gastritis and Eosinophilic Enteritis Patients Endure a Lengthy Path to Diagnosis and Experience Persistent Symptoms After Diagnosis (pdf)

American College of Gastroenterology (ACG) Annual Meeting

June 2019 Disease State

The Tortuous Path to Diagnosis of Eosinophilic Gastritis and Eosinophilic Gastroenteritis (EG/EGE) in the United States: A Real-World, Population-Based Study (pdf)

European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting

May 2019 Disease State

Mast Cells in Addition to Eosinophils Are Markedly Elevated in Patients with Eosinophilic Gastritis and/or Gastroenteritis (pdf)

Digestive Disease Week (DDW) Annual Meeting